Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
biigboy,
This is a stock board. No one is accurate in what they say. It is all opinion. Do I like Pred? Yes. Do I like the way it is acting? No. Am I long? Yes. Do I have as much as I once had? No. Do I believe they should have responded? Yes.
biigboy,
How do you know he is part of $13 trillion dollar investment firm ? Because he posted it? So far there has been no response by company with no news. I believe the earnings will speak for themselves. so far the shorts are still in control.
Thomas,
Nothing has been officially announced since 5/21 on Yahoo news
Thomas.............I have to agree with Snakess...........you state in your reply: However, pigs do get slaughtered and their trades and naked shorts have been tracked and are known over the last three months. How do you know they are being tracked? Maybe this is like left wing justice: one system for guys like Snake and myself and one set of rules for the rule breakers!
I for one still believe when the company never even addressed the allegations by saying something to the effect that "we vehemently deny the allegations made against us and will defend these allegations vehemently" was a mistake on their part and you can say all you want about this law firm but they have shown nothing to me and I practiced law.Their strategy is poor and I have seen no game plan laid out by anyone.
The only consistent thing I hear or see is the bird man telling us this is his favorite stock and the bird on his shoulder knocking his hat over his head 4 or 5 times before the idiot takes the cap off.
Reverse Long..........what proof do you have listing was denied? I think the earnings are more important as well as buying volume coming in
Thomas,
I think your posts are well written. I am long on PRED as some people on board personally know me; however, you post these excellent post and the company sits silent. They have made no comment since the Hidenberg bashing. You throw out numbers and indicate public news statements will be forthcoming but that is never the case. Meanwhile the stock dribbles down without any big buyers coming in.
Last week you posted picture of Robinson at NASDAQ. I do not care if he was there. I keep hearing next week, next week for NASDAQ. Well what date is he ringing the bell? When are earnings coming out? The earnings will tell the story.
I do not see anything in that posted article that mentioned PRED. I conclude from that article Pfizer is conducting their own programs and Predictive does not sound like they are in the plan
Thomas,
Excellent post.............but the question is will the SEC do anything about this and shouldn't a lawsuit be initiated against the brokerage house and brokers?
biliigboy,
Can you pleas send link to 93 patents?
Falcon,
I am not saying that. PRED I think happens to be a good one on its own merits. The pirate who claims he has never talked to company though has many unsubstantiated stupid comments like PRED has 92 patents. Call IR and see how many they really have
Pirate gets free shares and then unloads them into his pump of the stock.
Does anyone have proof that predictive has 92 patents as claimed by the pirate? Can someone post a link to evidence same
The pirate said he will buy predictive once it comes down to a certain price. The reality is that he never buys when he says he is going to buy. That is always evidenced by the volume.......there is none. He talks about company yet he said he speaks to no one at company.
Rainmaker.......there is only one pirate and one parrot and I think the parrot is smarter than the pirate. The pirate is only interested in his bounty and what is good for him. I have to believe that Thermo Fischer completely investigated this company before getting involved with them which is why I think the Hindenberg report is a crock of sh**t
Bloomberg Sign InSubscribe
Business
Predictive Technology Group Announces Launch of PGxPLUS+™ Pharmacogenomic Test and Reaches Clinical Study Enrollment
August 9, 2019, 9:15 AM EDT
SHARE THIS ARTICLE
Share
Tweet
Post
Email
Predictive Technology Group Announces Launch of PGxPLUS+™ Pharmacogenomic Test
and Reaches Clinical Study Enrollment Milestone
Enrollment reaches 350 patients for IRB-approved study focused on chronic pain
SALT LAKE CITY, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group,
Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease
identification and subsequent clinical intervention through precision
therapies, announces that its wholly owned subsidiary Predictive Laboratories,
Inc. has commercially launched PGxPLUS+, a pharmacogenomic test panel being
marketed to pain clinics for patients with chronic pain. PGxPLUS+ evaluates
genetic factors that play a major role in an individual’s response to
medications. In parallel, Predictive Laboratories has reached a milestone of
enrolling 350 patients with chronic pain into an Investigational Review
Board-approved clinical study aimed at providing additional insight into the
mechanisms of chronic pain and responses to pain therapies.
Predictive Technology Group is tackling chronic pain and the opioid crisis on
multiple fronts. Predictive has already developed and in-licensed important
prognostic DNA tests and novel treatments for osteoarthritis, lumbar disc
disease, endometriosis, and other conditions causing chronic pain. In 2016,
the Institute of Medicine estimated that up to one-third of the U.S.
population lives with ongoing pain. Chronic pain is often triggered by one of
these common conditions, and over time can develop into a chronic pain
syndrome, which is a disease itself.
The PGxPLUS+ panel is one of the most comprehensive pharmacogenetic tests
available on the market. Predictive’s test evaluates 112 genetic variants
across 38 genes that affect the metabolism of over 150 common medications,
including pain medications. More than 90% of the population has one or more
gene variants that affect the efficacy or safety of prescription drugs.
Variation in drug metabolism is largely determined by an individual’s genetic
profile, blood levels of a drug may vary up to 1,000-fold in similar patients
taking identical doses of the same drug. Pharmacogenomics is the study of the
role of our genome in drug responses.
Dr. Bryt Christensen, M.D., a pain specialist, reports, “The PGxPLUS+
pharmacogenetic test has been very helpful in my day-to-day practice. The
results give insights into why some patients are not responding to medications
as expected. With the help of these test results, I have been able to start
or switch medications for patients more successfully. The PGxPLUS+ test helps
me avoid prescribing medications that a patient won’t metabolize well, leading
to better and more personalized patient care.”
One-third of patients taking long-term opioid therapy for non-cancer chronic
pain either find their medication to be ineffective or they do not tolerate
the side effects of the treatment. In the clinical study, Predictive is
testing patients who are taking high doses of opioids [≥50 morphine milligram
equivalents (MME)/day] for genetic variants responsible for their underlying
disease, their metabolism of opioids, their intrinsic pain thresholds, and any
genetic predisposition to opioid addiction. Predictive plans to develop more
comprehensive treatment guidelines for pain based on predictive genetic
markers.
“The ability to effectively treat individuals in pain represents a significant
market opportunity and of even greater importance it serves an obligation of
society to alleviate the current pain and suffering of an individual in a
safer and more effective manner,” said Bradley Robinson, CEO of Predictive
Technology Group. “Our Company is both identifying the most effective ways to
treat pain at a personalized level and working to understand the underlying
cause of diseases like osteoarthritis, lumbar disc disease and endometriosis
to treat or prevent the root cause of the pain. We are pleased to add the
PGxPLUS+ test to our portfolio of regenerative medicine and diagnostic
products focused on treating chronic pain diseases.”
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through
predictive data analytics, novel gene-based diagnostics and companion
therapeutics through its subsidiaries Predictive Therapeutics, Predictive
Biotech, and Predictive Laboratories. These subsidiaries are focused on
endometriosis, scoliosis, degenerative disc disease, and human cell and tissue
products. The subsidiaries use genetic and other information as cornerstones
in the development of new diagnostics that assess a person’s risk of illness
and therapeutic products designed to identify, prevent and treat diseases more
effectively. Additional information is
available at Predtechgroup.com, Predrx.com, Predictivebiotech.com,
and Predictivelabs.com.
I am new to stock and long on it. Was happy with my pre-earnings purchase and it looked to me I made wise choice and then dropped from $2.46 to under $2. Does anyone know why? Earnings looked good to me. I bought stock for the drug pipeline. Anyone with stock a long time have an opinion?
well........let us see a copy of the class action lawsuit you filed so we can join in
Anyone know when they are supposed to release 2nd quarter earnings and revenue?
Brooklyn,
I maybe see NASDAQ down the road. Part of the reason we will not see NASDAQ now is because the parrot talked and over-hyped it too much. I do not see how a $2 stock can get on at this point
How do you know they are in quiet period?
Stockguru,
What plan in your opinion are they going to execute. You seem to have some good insight on this company so how do you see things playing out. Obviously we know they have to execute on all cylinders but is there something specific that IYO is going to occur?
A post was made stating that a class action suit was going to be initiated against Hidenburg and our positions and losses would need to be documented along with our other information. I assume that is in the works and was following up on it.
As I have expressed in previous posts I have no objection to the company's response to Hindenburg report 1, but with such "high powered" attorneys do you not think the release should have said that the company vehemently denied all allegations made against them since they had 96 hours to answer it?
When do we get the paperwork for the class action lawsuit against Hidenburg?
Biigboy7,
I am just giving my opinion. I am not saying the response was bad. I am just saying it was weak. They had 96 hours to prepare and they could have easily handled the release in 1 sentence. "we vehemently deny the allegations made by Hindenburg and will let the upcoming quarterly results of the company speak for itself."
I just did that for you for free in 5 seconds LOL. I did not need 96 hours and high powered attorneys. BTW where is the sign up for the class action?
He was on Friday and yes if you look at TD extended hours trading it is $1.95. If you have TD you can go in and buy it by putting in buy and hit day + ext. That is how it was done presumably by the shorts.Close it at $2 if you want. It trades until 6 or 8.
Brooklyn,
After hours stock closed @$1.95. What I said earlier before the 2nd hindenburg report still stands. PRED, imo did a poor job in responding to the 7-12 Hindenburg report. I can see the point in saying nothing and letting earnings and the stock performance speak for itself; however, they should have additionally said that we vigorously and vehemently catagoricaly deny the allegations set forth in the 7-12 report. How their great, expensive law firm did not say that was a mistake on PREDS part.
Another thing that bothers me is that ELGL and PRED have IMO the same PR firm. How do I know that? If you read the news release on 7-9 for ELGL it states call Richard Kaiser at 757-306-6090. That was the same number someone gave me to call PRED on Friday. I am certainly not a fan of ELGL but I do not like the fact that they are both tied to same PR firm. Just my opinion.
For purposes of clarification I am long on PRED, but when this came out I wanted all shareholders to know about it so they can do what they want to do. My personal opinion is that instead of not commenting on the 7-12 Hidenburg story they should have vehemently denied all allegations instead of choosing not to respond....but that is my opinion
Hidenburg just came out with follow up report:
Update: After 96 Hours, Predictive’s ‘Response’ Fails to Address a Single Point from Our Detailed Report
Published on July 15, 2019
GET OUR LATEST REPORTS DELIVERED TO YOUR INBOX
email address
Predictive Technology Group (the “Company”) barely responded this morning to our 10,000 plus word report that we released last Thursday, which had prompted shares to reprice more than 40% lower.
Our report documented extensive executive red flags, signs of insider self-dealing relating to the Company’s acquisitions, and issues with the Company’s procurement and marketing of its stem cell products, among other issues. It included over 190 source links, firsthand evidence, photos, and video to support its conclusions.
Given that a full 96 hours had elapsed since our report was published, we were expecting a thorough, detailed response from the Company.
Instead, the Company’s release this morning failed to address a single element of our report, claiming that it “will not dignify the opinion piece with a point-by-point response.” It bizarrely claimed that we are anonymous authors (we are not) and then quoted sections of our standard legal disclaimer, as if that somehow undermines our strong, well-founded views.
The Company’s lack of response just furthers our suspicions. Any time a company fails to address the facts lodged against it on a point by point basis it suggests, to us, that the facts are not on its side.
We believe it is of utmost importance to note what management has not said with today’s non-response. This is just a partial list of our findings, but should be an obvious starting point on items that shareholders deserve to know:
1. We showed Predictive’s Chairman and then director (up until recently) had settled earlier SEC fraud charges.
The Company’s response: none.
2. We showed (here, here and here) that Predictive’s 3 key original holders, who represented almost 90% of the original shareholder base, had previously been charged with securities fraud by federal or state regulators, including allegations of pump and dumps, boiler room sales, and false press releases.
The Company’s response: none.
3. We showed that the Company receives its donated birthing tissue from new moms who are often completely unaware that their ‘donations’ go to for-profit causes.
The Company’s response: none.
4. We showed that Predictive’s distributors use dubious sales tactics and aggressive claims to sell its products to elderly patients suffering from chronic pain, and provided multiple examples.
The Company’s response: none.
5. We showed that 4 out of 7 of Predictive’s acquisitions were entities based out of their own address before they were acquired, and that the acquisitions displayed hallmark signs of insider self-dealing. (Source documents: 1,2,3,4)
The Company’s response: none.
6. In one example, we showed that Renovo Biotech was formed less than 2 months earlier at Predictive’s own address before being acquired for $14 over million, largely for “trade secrets”.
The Company’s response: none.
7. In another example, we showed that Predictive CEO Bradley Robinson was listed as a manager/managing member of LifeCode Genetics just prior to its acquisition by Predictive, yet we found no Predictive filing disclosing any stake held by Robinson in the entity. We questioned whether Robinson had an undisclosed stake in this acquisition.
The Company’s response: none.
8. We showed that 90% of the purchase price for Predictive’s InceptionDX acquisition went to unnamed individuals in the Caymans and asked whether these individuals were arms-length.
The Company’s response: none.
9. We showed other examples of irregularities relating to the Company’s acquisitions and specifically encouraged the Company to provide the investing public with details of the shareholders of its acquisitions, as such information could easily clarify whether any related party dealings took place in these transactions.
The Company’s response: none.
10. We showed that the Company had seemingly altered a lab report to include conclusions about the number of viable cells in the product that were never in the original report, then used the altered report to market its products.
The Company’s response: none.
11. We expressed doubts about whether the Company’s products had any live stem cells or could legally make claims to have any live stem cells.
The Company’s response: none.
12. We showed that Predictive’s CEO had previously been sued and apparently settled lawsuits involving allegations of securities fraud and non-compliant marketing of a medical product.
The Company’s response: none.
13. We showed that Predictive’s CEO had originally reverse-merged an FDA-rejected medical technology into the entity that ultimately became Predictive.
The Company’s response: none.
14. We showed that top organizations studying endometriosis research expressed serious doubts about the Company’s diagnostics test and the ability to diagnose endometriosis via diagnostics alone.
The Company’s response: none.
15. We showed that the Company has historically missed its own near-term commercialization timelines for its diagnostic tests and expressed concerns that they may again miss their own timelines.
The Company’s response: none.
We believe shareholders deserve full transparency from management and today’s response brings them further from that goal, instead of closer to it.
Contrary to the Company’s statements, we stand by our research 100%. We haven’t covered one single share of our short position. In fact, we increased our short position this morning after the Company’s response and will look to increase it further.
Disclosure: We are (still) short shares of Predictive. See our original report for our full disclaimer and for the complete set of findings that management failed to address today
Topknotch,
How is it supposed to get uplisted now in light of allegations of fraud at $1.67 imo?
Just spoke to IR at PRED. Application is complete and going though the process at NASDAQ
Play,
I am a long term holder. All I said was that shorts were not bringing down the stock. It is the exercise of options that unlocked on March 29th as per 10-Q. I also said the promoter of the stock (not Barry--he is 3rd party) will get additional 750,000 shares of stock once they hit the NASDAQ. That is spelled out in 10-Q as well. If I recall it is on pages 36, 37 or look through pages 30-40
Chart Analysis
Website | Recent News
========================
Members,
The biotech industry has kept its promise for solid returns so far. The rally in some major biotechnology indexes reflects the same. In this context, the NASDAQ Biotechnology Index has returned 17.6% year to date. Following the trend, S&P Biotechnology Select Industry Index has returned around 29%.
With time, biotechnology is emerging as a favored sector for investors with some risk appetite and looking for attractive returns.
We've just identified a small-cap biotech company with NASDAQ aspirations, zero debt, and several promising treatments in their pipeline.
Please turn your immediate attention to PRED (Predictive Technology Inc.).
PRED operates through four segments:
Predictive Biotech
Predictive Laboratories
CellSure
Predictive Labs
The Predictive Biotech ( PB ) segment launched four products in 2017 and is currently generating quarterly revenues in excess of a $40 million annual run rate. Predictive Laboratories (PL) launched ARTguide™ in October 2018 for detecting genetic issues that may impact female fertility, including endometriosis and Fertility Dx in November, which adds a chromosomal microarray to the ARTguide diagnostic. In the future, PL will be responsible for advancing new candidates through the regulatory process. The third operating segment, CellSure ( CS ), is responsible for obtaining the source material for the cellular therapy segment. The fourth segment is Predictive Labs (PL) and was created with the acquisition of Taueret Laboratories in March 2019. PL will launch genetic tests for endometriosis and degenerative disc disease in the coming quarters.
Zacks Slaps on $8.00 Price Target
In their latest independent report, Zacks Small-Cap Research recently slapped a $8.00 price target on PRED , which equates to an upside of roughly +74% from today's alert price!
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person's risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com; Predrx.com; Predictivebiotech.com; and Predictivelabs.com.
Key reasons to own PRED shares:
Pursuing a near-term NASDAQ listing
Rapidly growing cellular therapy segment
Competency in cell and tissue processing
Cash flow from Biotech supports development activities in Therapeutics
Advance of cellular therapy candidates through regulatory approval process in Therapeutics
Library of 300,000 DNA samples and 31 million-individual genealogy database
Multiple new products launching in the Laboratory segment
ARTguide
Fertility Dx
ENDORisk
Transform CellSure into dominant source of tissue product for both internal and external markets
Development platform that can be applied to many genetic tests and cellular therapy applications
The Bullish Case for PRED
Predictive Technologies is growing in a number of underserved areas of the market including cellular therapy and women s health, initially entering the market in the fertility health space. More specifically, the company emphasizes clinical categories of endometriosis, scoliosis, degenerative disc disease and regenerative human celland tissue products. The common theme that connects currently commercialized products is their reliance on the self-pay market. This is an attractive space as products do not require time consuming approval by formularies or face restrictions by managed care or pharmacy benefit managers that create a barrier between product and patient and layer on substantial distribution costs. Success in cellular therapy and fertility health are expected to support efforts to advance many of the in-development medicines and services through the regulatory process.
In contrast to many development companies, Predictive is free cash flow positive, which provides funds for new launches, research and development efforts and sales initiatives. While we expect the company will consume the majority of operational cash generated to support growth in the sales force for both cellular therapy and genetic diagnostic tests, we see less reliance on capital markets for the company to achieve its objectives than a pure development company.
Both cellular therapy and genetic diagnostic tests are emerging areas in the health care space. For companies that can source, process and provide high quality medicines to the physicians who administer them, there is substantial opportunity. The same goes for genetic diagnostic tests that are developed and backed up by a genealogy database that can accelerate genetic discoveries. Predictive ownership of a proprietary genealogy database with over 30 million individuals and greater than 300,000 DNA samples provides a valuable resource that can isolate genes that are implicated in disease and generate tests that are highly accurate.
Predictive has identified a growth plan for each of its four segments. Predictive Biotech will continue to grow Section 361 product, which does not make any efficacy claims while Predictive Therapeutics will pursue Section 351 products that require review and approval from the FDA. CellSure will focus on procurement of tissue, optimizing cell yields and quality and offering storage services for new mothers. Predictive Laboratories, which was created and expanded through the acquisition of Taueret, will continue to develop and commercialize genetic diagnostic tests.
PRED Plans to Uplist to NASDAQ
Predictive currently trades on the over the counter (OTC) markets and has submitted an application to the NASDAQ. The company received comments back from the NASDAQ in late May and expects to file responses in June. This action was preceded by the necessary prerequisite of filing of Form 10 in December 2018 and subsequent filings of the second and third quarter 10-Qs. The NASDAQ has several requirements regarding
number of shareholders, market makers, market value, asset value and share price among others. Predictive satisfies all of the requirements and may be uplisted to the exchange this month.
There are only a few days left in June, so a potential uplisting could trigger some significant FOMO. An uplisting to NASDAQ tends to signify a company that is experiencing strong growth.
Financial Results
Predictive Technology Group filed its fiscal third quarter 2019 financial statements on May 20, 2019 for the three month period ending March 31, 2019. The company reported revenues of $11.3 million, which was comprised almost entirely from the human cell and tissue products (HCT/Ps) segment. $10 thousand was generated in the Diagnostics and Therapeutics segment. Revenues increased 167% over 3Q:18 levels. After cost of goods sold, gross profit was $6.5 million, representing a gross margin of 57.7%. Total operating expenses were $9.2 million, a 61% increase over the prior year. Operating loss fell to ($5.0) million from ($4.8) million in 3Q:18 on increased headcount and higher research and development costs. On a per share basis, loss was ($0.01). Cash balance as of March 31 was $1.8 million and no debt was carried on the balance sheet . For the first nine months of the fiscal year, cash from operations was $3.1 million, a sharp improvement from the ($2.6) million deficit in the prior year. Property and equipment investments equaled $2.7 million, bringing free cash flow to $0.3 million for the first three quarters of FY:19. Cash from financing activities was $1.7 million, resulting in a net increase in cash over the nine months of $0.6 million.
Zacks is estimating strong revenue increases in the years to come.
2018 Full Year Actual - $16.6M
2019 Full Year Estimate - $42M
2020 Full Year Estimate - $66.7M
2021 Full Year Estimate - $97.2M
Source: Zacks Small-Cap Research Report
Latest News
Thermo Fisher Scientific and Predictive Laboratories Announce Global Infertility Research Collaboration
Studies aim to elucidate infertility genetics for development of noninvasive test to support decision making and improved outcomes for women pursuing fertility treatment
Last Wednesday, Thermo Fisher Scientific announced today that it has entered into a global research collaboration with Predictive Laboratories, a wholly owned subsidiary of Predictive Technology Group, Inc., (OTC PINK: PRED ) focused on studying the genetic factors underlying infertility in women. The work will utilize Thermo Fisher's various offerings for reproductive health, including Applied Biosystems CarrierScan Assay, Ion ReproSeq PGS Assay, CytoScan Dx Assay, and Ion AmpliSeq Exome RDY for whole exome sequencing.
Infertility has many potential causes, which may involve one or both partners. In some cases, no cause of the condition can be determined, leading the infertility to be described as "unexplained." The most common causes among women are irregular ovulation, blockage of the fallopian tubes, and endometriosis. The American College of Obstetrics and Gynecology (ACOG) reports that at least 40 percent of women with infertility have endometriosis.
Endometriosis occurs when the endometrial tissue that lines the uterine wall grows in other areas of the body outside of the uterus. While the symptoms are well-characterized, including pelvic pain, heavy periods, and pain during sexual intercourse or bowel movements, the disease is highly variable and many women have asymptomatic endometriosis, which has a significant impact on their fertility. The studies with Predictive Laboratories aim to elucidate the genetic basis of this condition, which is expected to more accurately define which women will experience infertility.
"Infertility among women who seek to conceive has become an increasingly common condition, which leads to much frustration and financial burden as they seek alternative solutions," said Bradley Robinson, CEO of Predictive Technology Group. "Our collaboration with Thermo Fisher brings together our innovative research and development capabilities with market-leading next generation sequencing technology to better understand the genetics of infertility for future development of a diagnostic solution."
Worldwide, around 70 to 80 million couples currently experience infertility, which causes significant depression, anxiety, and loss of work productivity. The ability to identify women who will experience trouble conceiving will allow for early intervention and personalized treatment planning that may result in fewer cycles to achieve a successful pregnancy.
"We look forward to this exciting and important work with Predictive Laboratories to better understand infertility in women," said Yan Zhang, general manager, reproductive health at Thermo Fisher. "With the combination of our partner's expertise and our advanced solutions for genetic analysis, we are committed to reducing the future financial and emotional burden couples face while undergoing fertility treatment."
Market Outlook:
Endometriosis affects an estimated 200 million women worldwide6 and is frequently misdiagnosed, preventing its early and proper treatment
30-50% of women with endometriosis may experience fertility issues
One of the leading causes of female infertility
Worldwide, around 70 to 80 million couples currently experience infertility, which causes significant depression, anxiety, and loss of work productivity. The ability to identify women who will experience trouble conceiving will allow for early intervention and personalized treatment planning that may result in fewer cycles to achieve a successful pregnancy.
No effective non-surgical method to diagnose
No therapeutic cure
Technical Analysis
We've done our very own chart analysis and see the potential for a move of over +121%.
Perfect Wave 3 target to the 1.618 fibonacci extension now ready to target 2.618 fibonacci for wave 5
The Bottom Line
In our opinion, PRED has all of the characteristics of a winner in both the short and long term.
Strong Revenue Growth
Plans to uplist to the Nasdaq exchange
ZERO Debt
Strong Product Pipeline
Bullish Technicals
As such, we ask that all members start their research on PRED immediately, and consider building a position tomorrow morning at 9:30AM EST
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
I have said many times on this board that I do not believe it is shorts shorting stock. Rather I think they are option warrants selling as per 10-Q. If you read 10-Q, the 3rd party who provided free shares to Barry gets additional 750,000 unless I read that wrong and I do not know if those shares are restricted.
NOTE 11 STOCK OPTION PLAN
In 2015 a Stock Option Plan was adopted to advance the interests of the Company and its shareholders by helping the Company obtain and retain the services of employees, officers, consultants, independent contractors and directors, upon whose judgment, initiative and efforts the Company is substantially dependent, and to provide those persons with further incentives to advance the interests of the Company. Eligible participants include employees, officers, certain consultants, or directors of the Company or its subsidiaries.
The aggregate number of shares of Option Stock that may be issued pursuant to the exercise of Options granted under this Plan will not exceed fifteen percent (15%) of the total outstanding shares of the Company's common stock, par value $.001 per share.
On March 7, 2019, The Company entered into an agreement with a consultant for business development services. In consideration for these services, the Company granted options to the consultant exercisable for 3,500,000 shares of the Company’s common stock with a strike price equal to the closing price of the Company’s common stock on the date of grant. Options to acquire 1,000,000 shares vested upon issuance, and 750,000 vest upon the Company’s listing on a major stock exchange. The remaining 1,750,000 options vest in five equal quarterly tranches of 350,000 options starting on September 1, 2019. The warrants expire five years from the date of issuance.
A summary of option activity is as follows for the fiscal period ended March 31, 2019 and the fiscal year ended June 30, 2018:
March 31, 2019
June 30, 2018
Number
of
shares
Weighted average exercise price
Number
of
shares
Weighted
average exercise price
Options outstanding at beginning of period
5,613,500
$
0.80
300,000
$
1.00
Options granted
7,070,000
1.17
5,313,500
0.79
Less:
Options exercised
(3,333)
.94
-
-
Options canceled or expired
(1,092,667)
.93
-
-
Options outstanding at end of period
11,587,500
$
1.02
5,613,500
$
0.80
Options exercisable at end of period
6,103,125
$
0.93
3,008,000
$
0.75
-27-
Share based compensation expense for the 3 and 9 month periods ended March 31, 2019 was $2,634,969 and $4,238,790, respectively. Share based compensation expense for the 3 and 9 month periods ended March 31, 2018 was $2,919,232 and $8,369,120, respectively. Share based compensation expense is included in selling, general, and administrative expense on the consolidated statement of operations.
As of March 31, 2019, there was $8,244,839 of total unrecognized share-based compensation expense related to stock options and warrants that will be recognized over a weighted-average period of 2.2 years
If you read 10-K there are warrants that can be exercised starting at .71. That was from prior years. You are correct about the recent warrants.
Peachman,
If you read the 10-Q it could be people exercising the sale of warrants that were held under $1 and not shorts
Alleyba says...............
............that he received the same alert from Wallstreet Alerts .org and the stock they are pitching tomorrow will be Predictive. All the facts they gave fit PRED. Release is 9:30 a.m. In my opinion it is a match. How much buying will come in I cannot say ....but for sure it is a match. Stock looks like it is opening at 4.76
Maz,
what are your concerns?
Read the 10-Q it is not shorts. I believe conversion of warrants